Skip Navigation


European Heart Journal Advance Access originally published online on July 4, 2006
European Heart Journal 2006 27(16):1893-1894; doi:10.1093/eurheartj/ehl140
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/16/1893    most recent
ehl140v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lip, G. Y.H.
Right arrow Articles by Shantsila, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lip, G. Y.H.
Right arrow Articles by Shantsila, E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Anticoagulation for stroke prevention in atrial fibrillation: is gender important?

Gregory Y.H. Lip*, Timothy Watson and Eduard Shantsila

Haemostasis, Thrombosis and Vascular Biology Unit, University Department of Medicine, City Hospital, Dudley Road, Birmingham B18 7QH, England, UK

* Corresponding author. Tel: +44 121 507 5080; fax: +44 121 554 4803. E-mail address: g.y.h.lip@bham.ac.uk

This editorial refers to ‘Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials’{dagger} by M. Gomberg-Maitland et al., on page 1947

The first 10% of the full text of this article appears below.

The presence of atrial fibrillation (AF) confers a five-fold increased risk of stroke, a figure that may rise to as high as 17 times in the presence of structural heart disease, in particular mitral stenosis. It is estimated that 15% of all strokes may be directly attributable to AF, but of greater concern is that when patients with AF have a stroke, they have a much worse outcome. Being an increasingly more prevalent arrhythmia and given the increasing mean age of the general population, AF presents a significant economic burden.

Why does AF confer such a high risk of stroke and thrombo-embolism? The loss of co-ordinated atrial contraction in AF, associated with stasis and structural (and electrical) remodelling . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials
Mardi Gomberg-Maitland, Nanette K. Wenger, Jan Feyzi, Maria Lengyel, Annabelle S. Volgman, Palle Petersen, Lars Frison, and Jonathan L. Halperin
EHJ 2006 27: 1947-1953. [Abstract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 StrokeHome page
P. Appelros, B. Stegmayr, and A. Terent
Sex Differences in Stroke Epidemiology: A Systematic Review
Stroke, April 1, 2009; 40(4): 1082 - 1090.
[Abstract] [Full Text] [PDF]

Home page
 JWatch Women's HealthHome page
Reducing Stroke Risk in Patients with Atrial Fibrillation
Journal Watch Women's Health, October 5, 2006; 2006(1005): 3 - 3.
[Full Text]